It was recently announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) designated nintedanib, an oral triple angiokinase inhibitor by Boehringer Ingelheim, as a Promising Innovative Medicine (PIM). Nintedanib is not yet available to malignant pleural #mesothelioma patients in the UK, but with this designation, the drug could be available to patients […]
In 2015, data was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting from a Phase III French study that demonstrated improved survival rates for patients who received bevacizumab (Avastin® Genentech, Inc.) in addition to the standard chemotherapy regimen of pemetrexed/cisplatin.
The outcome of the study prompted the independent French cooperative group and Genentech […]
If you live In the United States where pharmaceutical companies advertise directly to consumers, in the last few years you’ve likely seen many ads for drugs whose unbranded names end in “mab.” Many of the advertised drugs are used to treat disorders such as rheumatoid arthritis, Crohn’s disease, psoriasis, asthma, Alzheimer’s disease, to mention a […]
Last week, at the World Conference on Lung Cancer, Dr. Raffit Hassan presented promising data on a novel agent, anetumab ravtansine, also known as BAY 94-9343. Anetumab ravtansine is an antibody-drug conjugate directed against the target molecule mesothelin which is highly expressed on mesotheliomas.
“Anetumab ravtansine shows encouraging efficacy in patients with advanced mesothelioma which warrants […]